Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 22, 2017 (9 years ago)

Famciclovir Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Temperature Abuse: Complaints of tablets being wet and stuck together with tablet coating peeled and disintegrated as a result of prolonged exposure to high temp during distribution.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Famciclovir Tablets, 500 mg, 30-count bottles, Rx Only, Manufactured For: Camber Pharmaceuticals. Inc. Piscataway, NJ 08854 By: HETERO, Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar-509 301, India. NDC 31722-708-30

Affected NDC 31722-0708-30

Compare with the code on your package — it is the most precise check available.

Drug: Famciclovir

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Famciclovir
NDC 31722-0708
500 mg/1 Tablet, Film Coated
Oral
Camber Pharmaceuticals, Inc. Rx
Recalling firm
Hetero Labs Limited Unit V
NDC code
31722-708-30
Origin
India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0415-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Famciclovir recalls

See all
Class III · Low risk

Famciclovir Tablets

Presence of Foreign Substance- Black hair strand found attached to a tablet in a sealed bottle.

Ongoing Particulate / foreign matter Macleods Pharmaceuticals Ltd NDC 33342-026-07 D-0509-2025
Class II · Moderate risk

Famciclovir tablets

Failed impurities/ degradation specifications: Product was above specification for unknown impurities.

Terminated Impurity / degradation AVKARE Inc. NDC 50268-307-13 D-0610-2017
Class II · Moderate risk

Famciclovir active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-671-2015
Class II · Moderate risk

Famciclovir

Labeling: Label Mixup: FAMCICLOVIR, Tablet, 500 mg may have potentially been mislabeled as one of the following drugs: TOLTERODINE TARTRATE ER, Capsule, 4 mg, NDC 00009519101, Pedigree: AD49448_1, EXP: 5/17/2014; THIAMINE HCL, Tablet, 100 mg, NDC 00904054460, Pedigree: AD54559_1, EXP: 5/20/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-851-2014

Other recalls by Hetero Labs Limited Unit V

All 2017 recalls
Class II · Moderate risk

Pantoprazole Sodium

Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."

Ongoing Failed specification Hetero Labs Limited (Unit V) NDC 31722-713-10 D-0484-2026
Class II · Moderate risk

Montelukast Sodium Tablets

Discoloration: A complaint was received from a pharmacist for the presence of blue specks on tablets.

Terminated Failed specification Hetero Labs Limited Unit V NDC 31722-726-30 D-1213-2018
Class I · High risk

Montelukast Sodium Tablets 10 mg

Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.

Ongoing Labeling / mix-up Hetero Labs Limited Unit V NDC 31722-726-30 D-0081-2019